Lisi S.A.
FII.PA · Euronext Paris · EUR
66,90EUR
−0,30 (−0,45 %)Stand 11. Nov., 13:57
Kennzahlen
- Eröffnung
- 67,60
- Vortag
- 67,20
- Tagesspanne
- 66,50 – 68,30
- 52 Wochen
- 45,75 – 72,60
- Volumen
- 11.600
- Ø Volumen
- 30.282
- Börsenwert
- 3,06 Mrd. €
- KGV
- 18,7
- Gewinn je Aktie (TTM)
- 4,87
- Dividendenrendite
- 0,7 %
- Beta
- 1,1
- Nächste Zahlen
- 18. Feb. 2027
Finanzen
| EUR | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 1,75 Mrd. | 1,79 Mrd. | 1,63 Mrd. | 1,43 Mrd. | 1,16 Mrd. |
| Herstellungskosten | 1,63 Mrd. | 953,73 Mio. | 879,18 Mio. | 1,25 Mrd. | 1,03 Mrd. |
| Bruttogewinn | 120,85 Mio. | 840,32 Mio. | 751,27 Mio. | 178,49 Mio. | 131,36 Mio. |
| Forschung und Entwicklung | 0 | 0 | 0 | 321 Mio. | 267 Mio. |
| Vertrieb und Verwaltung | 0 | 0 | 0 | −201 Mio. | −168,14 Mio. |
| Operatives Ergebnis | 161,01 Mio. | 91,94 Mio. | 90,68 Mio. | 89,1 Mio. | 66,61 Mio. |
| EBITDA | 253,91 Mio. | 241,33 Mio. | 181,5 Mio. | 182,95 Mio. | 161,25 Mio. |
| Nettogewinn | 139,72 Mio. | 56,01 Mio. | 37,53 Mio. | 56,96 Mio. | 44,05 Mio. |
| Gewinn je Aktie (verwässert) | 3,01 | 1,20 | 0,81 | 1,06 | 0,82 |
Bewertung
Letzte 12 Monate
- KGV
- 18,7
- Kurs-Umsatz-Verhältnis
- 1,8
- Kurs-Buchwert-Verhältnis
- 2,7
- PEG
- 0,1
- Bruttomarge
- 8,1 %
- Operative Marge
- 10,0 %
- Nettomarge
- 9,6 %
- Verschuldungsgrad
- 0,4
- EV/EBITDA
- 12,9
- Eigenkapitalrendite
- 14,7 %
- Kapitalrendite (ROIC)
- 7,2 %
- Free-Cashflow-Rendite
- 2,2 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 6,9 % | 46,8 % | 46,1 % | 12,5 % | 11,3 % |
| Operative Marge | 9,2 % | 5,1 % | 5,6 % | 6,3 % | 5,7 % |
| Nettomarge | 8,0 % | 3,1 % | 2,3 % | 4,0 % | 3,8 % |
| KGV | 17,4 | 17,9 | 28,4 | 18,0 | 34,2 |
| Kurs-Umsatz-Verhältnis | 1,4 | 0,6 | 0,7 | 0,7 | 1,3 |
| Kurs-Buchwert-Verhältnis | 2,2 | 1,0 | 1,1 | 0,9 | 1,4 |
| Verschuldungsgrad | 0,5 | 0,7 | 0,7 | 0,4 | 0,5 |
| Liquidität 3. Grades | 2,0 | 1,7 | 1,6 | 1,7 | 1,7 |
| Dividendenrendite | 0,7 % | 1,4 % | 0,7 % | 1,5 % | 0,5 % |
| Unternehmenswert | 2,66 Mrd. | 1,49 Mrd. | 1,57 Mrd. | 1,32 Mrd. | 1,77 Mrd. |
| EV/EBITDA | 10,5 | 6,2 | 8,6 | 7,2 | 11,0 |
| Eigenkapitalrendite | 12,9 % | 5,6 % | 4,0 % | 5,1 % | 4,2 % |
| Kapitalrendite (ROIC) | 6,7 % | 3,7 % | 3,2 % | 3,9 % | 2,9 % |
| Free-Cashflow-Rendite | 3,1 % | 8,0 % | 3,6 % | 1,8 % | 3,3 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −2,6 % | +10,0 % | +14,4 % | +22,5 % | −5,4 % |
| Bruttogewinn | −85,6 % | +11,9 % | +320,9 % | +35,9 % | +10,4 % |
| Operatives Ergebnis | +75,1 % | +1,4 % | +1,8 % | +33,8 % | +337,0 % |
| Nettogewinn | +149,5 % | +49,2 % | −34,1 % | +29,3 % | +218,0 % |
| Gewinn je Aktie | +150,8 % | +48,1 % | −23,6 % | +29,3 % | +217,1 % |
| Freier Cashflow | −7,5 % | +110,5 % | +109,4 % | −62,8 % | −55,0 % |
| Dividende je Aktie | +25,7 % | +76,3 % | −39,3 % | +107,5 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 1,92 Mrd. | 2,13 Mrd. | 2,33 Mrd. |
| Umsatz (Tief – Hoch) | 1,89 Mrd. – 1,93 Mrd. | 2,09 Mrd. – 2,17 Mrd. | 2,29 Mrd. – 2,4 Mrd. |
| Gewinn je Aktie (Ø) | 2,84 | 3,58 | 4,26 |
| Gewinn je Aktie (Tief – Hoch) | 2,67 – 3,03 | 3,31 – 3,93 | 3,57 – 4,92 |
| Analysten | 4 | 6 | 7 |
Quartalszahlen
Nächste Zahlen: 18. Feb. 2027| Juli 2026 | Feb. 2026 | Juli 2025 | Mai 2025 | Okt. 2024 | Apr. 2024 | Okt. 2023 | Apr. 2023 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | 1,36 | 2,22 | 0,83 | 0,52 | 0,68 | 0,52 | 0,29 | 0,44 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 944,07 Mio. | 769,15 Mio. | 1,01 Mrd. | 890,46 Mio. | 929,63 Mio. | 808,68 Mio. | 821,77 Mio. | 730,04 Mio. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 30. Apr. 2026 | 6. Mai 2026 | 0,46 |
| 30. Apr. 2025 | 5. Mai 2025 | 0,39 |
| 30. Apr. 2024 | 3. Mai 2024 | 0,27 |
| 17. Apr. 2023 | 19. Apr. 2023 | 0,13 |
| 4. Mai 2022 | 6. Mai 2022 | 0,29 |
| 3. Mai 2021 | 5. Mai 2021 | 0,14 |
| 30. Apr. 2019 | 3. Mai 2019 | 0,44 |
| 2. Mai 2018 | 4. Mai 2018 | 0,48 |
| 5. Mai 2017 | 9. Mai 2017 | 0,45 |
| 5. Mai 2016 | 9. Mai 2016 | 0,39 |
| 5. Mai 2015 | 7. Mai 2015 | 0,37 |
| 2. Mai 2014 | 7. Mai 2014 | 1,70 |
Aktiensplits
- 12. Sept. 20145:1
- 29. Juni 19985:1
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
Lisi S.A. is a global provider of specialized assembly and component solutions, primarily serving the aerospace, automotive, and medical sectors. The company organizes its operations into three distinct divisions: LISI Aerospace, LISI Automotive, and LISI Medical. LISI Aerospace specializes in advanced aircraft components, including titanium fasteners, lightning protection, safety locking mechanisms, and fuse pins. Their contributions to the LEAP engine encompass compressor blades, struts, and composite fan blade leading edges. They also produce air intake lipskins for Airbus aircraft, semi-machined gears for power transmission, stator vanes, and satellite antenna mounting brackets for both airplanes and helicopters. LISI Automotive delivers a broad spectrum of fastening and component solutions for vehicles. This includes guide pins, electric parking brake elements, complete braking systems, and direct engine injection parts. They supply various fasteners like screws, nuts, and specialized clips for interior and exterior trim, alongside components for seat belt mechanisms, motor systems, and safety applications. The division also focuses on assembly optimization, offering cable ducts, battery fastening systems, intricate power transmission parts, and standard automotive fasteners. Furthermore, they provide clipped fastening solutions for both internal and external cladding, specialized fasteners for tubes and cables, and products designed to reduce weight and streamline assembly processes. Their portfolio extends to critical components for braking, fluid management, seat adjustment, and interior safety systems. LISI Medical is involved in the complete lifecycle of medical device development, from initial design and modeling through prototyping, pre-series production, material selection, process validation, and inventory management. They manufacture a range of orthopedic reconstruction implants for shoulders, hips, knees, and extremities, along with associated surgical instruments. The division also produces various surgical tools, such as blades, scissors, staplers, and pliers. Additionally, they provide spinal and trauma implants, including connectors, screws, cages, plates, and prostheses, specifically designed for treating trauma and facilitating osteosynthesis. Established in 1777, the company, originally known as GFI Industries, adopted the name LISI S.A. in 2002. Headquartered in Belfort, France, it operates as a subsidiary of Compagnie Industrielle De Delle S.A.
Führung
- Emmanuel ViellardCEO, Member of Executive Board & Director
- Alexis PolinChief HR Officer & Member of Executive Board
- Christian DarvilleSenior VP of Administration & Strategic development for North America and Member of Executive Board
- Christophe MartinChief Industrial & Procurement Officer and Member of Executive Board
- Emmanuel NeildezCEO of LISI AEROSPACE & Member of Executive Board
- Geoffroy KohlerChief CSR, Risks & Compliance Officer and Representative Director
- CEO
- Emmanuel Viellard
- Mitarbeitende
- 9.455
- Hauptsitz
- Belfort, BFC, FR
- Sektor
- Industrials
- Branche
- Aerospace & Defense
- Börsengang
- 3. Jan. 2000
- Website
- lisi-group.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.